These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24454606)

  • 1. Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.
    Adli Oel Y; Corcos J
    Can Urol Assoc J; 2014 Jan; 8(1-2):E61-7. PubMed ID: 24454606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin for the treatment of lower urinary tract symptoms: a review.
    Sahai A; Khan M; Fowler CJ; Dasgupta P
    Neurourol Urodyn; 2005; 24(1):2-12. PubMed ID: 15578628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
    Utomo E; Groen J; Blok BF
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
    Leippold T; Reitz A; Schurch B
    Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on urological care in multiple sclerosis patients.
    Moussa M; Abou Chakra M; Papatsoris AG; Dabboucy B; Hsieh M; Dellis A; Fares Y
    Intractable Rare Dis Res; 2021 May; 10(2):62-74. PubMed ID: 33996350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of urodynamics in stress urinary incontinence: A critical appraisal.
    Yande SD; Joglekar OV; Joshi M
    J Midlife Health; 2016; 7(3):119-125. PubMed ID: 27721639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis.
    Onal B; Siva A; Buldu I; Demirkesen O; Cetinel B
    Int Braz J Urol; 2009; 35(3):326-33. PubMed ID: 19538768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
    Kuo HC
    Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonneurogenic voiding disorders in children and adolescents: clinical and videourodynamic findings in 4 specific conditions.
    Glassberg KI; Combs AJ; Horowitz M
    J Urol; 2010 Nov; 184(5):2123-7. PubMed ID: 20850821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia.
    Huang M; Chen H; Jiang C; Xie K; Tang P; Ou R; Zeng J; Liu Q; Li Q; Huang J; Huang T; Zeng W
    J Rehabil Med; 2016 Oct; 48(8):683-687. PubMed ID: 27563834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases.
    Wiedemann A; Kaeder M; Greulich W; Lax H; Priebel J; Kirschner-Hermanns R; Füsgen I
    World J Urol; 2013 Feb; 31(1):229-33. PubMed ID: 22227822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.
    Yonnet GJ; Fjeldstad AS; Carlson NG; Rose JW
    Int J MS Care; 2013; 15(2):66-72. PubMed ID: 24453765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Urodynamic Analysis of Urinary Dysfunction in Multiple Sclerosis.
    Wang T; Huang W; Zhang Y
    Chin Med J (Engl); 2016 Mar; 129(6):645-50. PubMed ID: 26960366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and rehabilitation of neurologic patients with lower urinary tract dysfunction.
    Drake MJ
    Handb Clin Neurol; 2015; 130():451-68. PubMed ID: 26003260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
    Jiang YH; Chen SF; Kuo HC
    Int Neurourol J; 2020 Dec; 24(4):301-312. PubMed ID: 33401351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives.
    Barbalias GA; Nikiforidis G; Liatsikos EN
    J Urol; 1998 Jul; 160(1):106-11. PubMed ID: 9628615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.